The global, randomized, open-label, phase III POSEIDON trial was conducted to test the PD-L1 antibody durvalumab with or without the CTLA-4 inhibitor tremelimumab in addition to chemotherapy Q3W for 4 cycles compared to platinum-based chemotherapy Q3W for up to 6 cycles.
Especially after frontline chemoimmunotherapy, treatment options are limited in patients with small-cell lung cancer (SCLC). Notch ligand delta-like ligand 3 (DLL3) represents a potential therapeutic target as it is aberrantly expressed on the surface of SCLC cells. By binding both DLL3 and CD3, the bispecific T cell engager (BiTE©) tarlatamab induces T-cell–mediated tumor lysis.
Lobar resection has been the surgical standard of care for cT1 N0 non–small-cell lung cancer (NSCLC) for decades, while sublobar resection (SLR) was reserved for a subset of patients with marginal pulmonary reserve. However, the recently published JCOG0802/WJOG4607L study showed that in fit patients with cT1a N0 tumors sized ≤ 2 cm, segmentectomy was not inferior to lobectomy regarding overall survival (OS).
The EGFR-MET bispecific antibody amivantamab is being assessed in combination with the third-generation EGFR tyrosine kinase inhibitor lazertinib in the multicohort CHRYSALIS-2 trial in patients with EGFR-mutant non–small-cell lung cancer (NSCLC). Results from the cohort receiving amivantamab/lazertinib in addition to carboplatin/pemetrexed (n = 20) were presented at WCLC 2022 by Marmarelis et al.
The International Association for the Study of Lung Cancer (IASLC) 2022 World Conference of Lung Cancer (WCLC) was held in Vienna, Austria, and virtually from 6th to 9th August and saw leading scientists, researchers and patient advocates from around the world gather again to discuss the most exciting updates in the field of lung cancer and thoracic oncology with key updates summarized in 380 invited lectures, 60 oral and 84 mini oral presentations, as well as almost 1,000 posters and ePosters.
